Ormefen Tablet contains Centchroman 60mg, a non-steroidal selective estrogen receptor modulator used primarily as a contraceptive and for the management of hormone-related disorders. Centchroman exhibits anti-estrogenic effects on the uterus and breast tissue while demonstrating estrogenic activity on bones and the cardiovascular system, making it effective in preventing pregnancy and regulating menstrual cycles. It is commonly prescribed as a weekly oral contraceptive due to its prolonged action and favorable safety profile. Ormefen Tablet is also utilized in the treatment of dysfunctional uterine bleeding, mastalgia, and as an adjunct therapy in hormone-responsive breast cancer. The medication works by modulating estrogen receptors, thereby inhibiting ovulation and altering the endometrial lining to prevent implantation. Its non-steroidal nature reduces the risk of steroid-associated adverse effects. Patients are advised to take Ormefen Tablet as directed by a healthcare professional, typically starting within five days of menstruation onset. Common side effects may include mild gastrointestinal discomfort, headache, or menstrual irregularities. It is contraindicated in individuals with known hypersensitivity to Centchroman, thromboembolic disorders, or hormone-sensitive malignancies. Regular follow-up is recommended to monitor therapeutic efficacy and detect any adverse reactions.